Navigation Links
Pharmexa and Affitech to Combine Operations to Create a New Antibody Therapeutics Company
Date:3/4/2009

COPENHAGEN and OSLO, March 4 /PRNewswire/ -- Pharmexa A/S and Affitech AS announced today that they have entered into a conditional agreement to merge the two companies by means of a share for share acquisition by Pharmexa A/S of the private Norwegian company, Affitech AS. The purpose of the merger is to transform Pharmexa from a cancer and infectious disease vaccine business into a company focused on the research and development of human antibody therapeutic drugs.

Under the terms of the merger agreement, Pharmexa will offer to acquire 100% of the outstanding and issued share capital of Affitech AS in exchange for newly issued shares in Pharmexa. On completion of the transaction, Affitech shareholders will own approximately 70% and Pharmexa shareholders 30% of the merged Company. The combined Company will be renamed Affitech A/S and it is the aim to continue the Company's listing on the Nasdaq OMX exchange in Copenhagen. The existing Affitech drug discovery business in Oslo will be renamed Affitech Research AS.

As part of the merger certain Affitech shareholders will undertake to participate in a new share issue which Pharmexa expects to take place during Q2 or Q3 2009.

Aims of the Merger

The acquisition of Affitech by Pharmexa is intended to create a new European biopharmaceutical company listed on the Nasdaq OMX Copenhagen exchange dedicated to the discovery and development of human antibody therapeutics in cancer and other diseases of unmet medical need. The integration of the two companies marks a transformational event by combining the antibody discovery expertise and early product pipeline of Affitech with the drug development capabilities, processes and infrastructure of Pharmexa. The combined Company will focus its activities entirely in the field of human antibody therapeutics. Antibodies constitute one of the most commercially successful fields in the biotechnology
'/>"/>

SOURCE Affitech AS
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Affitech Acquires Pharmexas Diabody Technology
2. Affitech Announces Second Milestone in Roche Antibody Discovery Collaboration
3. Affitech Appoints Dr. Keith McCullagh as Chairman
4. Affitech and Omeros Enter Into Antibody Discovery and Development Agreement
5. The New MACSQuant(TM) Analyzer Combines Cell Enrichment and Flow Cytometry
6. Irvine Dermatologist Begins In-office Clinical Studies -- Nissan Pilest, MD Combines Multi-Use Botox in Laser Resurfacing Clinical Studies
7. SuperGens MP-470 Demonstrates Clinical Tumor Regression When Combined with Standard of Care Chemotherapy
8. Old and new therapies combine to tackle atherosclerosis
9. BioHorizons Global Symposium 2008 Combines Record Attendance with Groundbreaking Technology
10. Elseviers Engineering Village Search Platform Combines the American Geological Institutes Georef Database With Google Maps
11. Study Suggests Risperidone Long-Acting Injection Combined with Standard Treatment Helped Delay Time to Relapse in Patients with Bipolar Disorder

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)... , CALGARY, Dec. 2 /PRNewswire-FirstCall/ - O...ny") (TSX:ONC; NASDAQ: ONCY ) announced today that...offering, the underwriters have exercised in full ...ional 637,500 units. Each unit is comprised of one...arrant, and was sold at a price of US$3.00 per uni...
(Date:12/2/2009)... , SINGAPORE, Dec. 2 S*BIO Pte...el oral JAK2 inhibitor, SB1518, at The American So...tion in New Orleans. ,, Data will be presented ...lation trial of SB1518 detailing its safety, toler...) profile in dose levels ranging from 100 to 600 m...
(Date:12/2/2009)... The Scientist, a leading scientific...metrics’ Evolve “Intelligent” EM...dquo;Top 10 Innovations of 2009. , ...™ EMCCD camera from Photometrics ®, a ...and EMCCD cameras for the life sciences, was ranke...
(Date:12/1/2009)... , NEW YORK, Dec. 1 Reportlink... is available in its catalogue: ,, Industrial ...w.reportlinker.com/p0164431/Industrial-Enzymes---A...es market is an oligopoly with few strong players ...ket activities. Keen competition and commoditizati...
Breaking Biology Technology:Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters' Over-Allotment Option 2Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters' Over-Allotment Option 3Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters' Over-Allotment Option 4S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 4S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 5The Scientist Names Photometrics' Evolve EMCCD Camera One of the “Top 10 Innovations” of 2009 2The Scientist Names Photometrics' Evolve EMCCD Camera One of the “Top 10 Innovations” of 2009 3Reportlinker Adds Industrial Enzymes - A Global Market Report 2Reportlinker Adds Industrial Enzymes - A Global Market Report 3Reportlinker Adds Industrial Enzymes - A Global Market Report 4Reportlinker Adds Industrial Enzymes - A Global Market Report 5Reportlinker Adds Industrial Enzymes - A Global Market Report 6Reportlinker Adds Industrial Enzymes - A Global Market Report 7Reportlinker Adds Industrial Enzymes - A Global Market Report 8Reportlinker Adds Industrial Enzymes - A Global Market Report 9Reportlinker Adds Industrial Enzymes - A Global Market Report 10
... article, Michael Rosen argues that Big Pharma "w...gests that this will be a good thing. But Big Phar...onal pharmaceuticals. This strategy has not been p...ne will be well-served if Big Pharma adopts this s... if at least some "biogenerics" eventually are app...
... you learn a lot of things. , ,You learn that most...he Hitchhikers Guide to the Galaxy and their faith...hies like Linux and hate Microsoft. Among many oth...hies how they really, really feel about technology...ourself, you may have had a taste of the take by t...
...e investor group that has weathered a couple of sl...ip of tech entrepreneur Pehr Anderson. , ,The ange...gh net worth, allows investors to pool strategies,...ments. It began in 2000 with 13 investors, and aft...ade fewer deals over the last two years. , ,Anders...
Other Biology Technology:Big Pharma already has a generic strategy, but needs new direction 2Big Pharma already has a generic strategy, but needs new direction 3How to tackle the divide between techies and non-techies at work 2How to tackle the divide between techies and non-techies at work 3How to tackle the divide between techies and non-techies at work 4Boston entrepreneur to enliven Milwaukee angel group 2
(Date:12/1/2009)...n-Ari, winner of the 2009 Inserm Grand Prix., Ev...tment to paying tribute to outstanding,work perfo...ring talents, Inserm intends to,demonstrate the d...y,s biological, medical and,health research, and ...o carry out and,drive this research each day. The...
(Date:12/1/2009)...first, a Monash University-led international resea...the output of the next generation of solar cells. ...ion with colleagues from the universities of Wollo...-sensitised solar cells with a three-fold increase...viously reported tandem dye-sensitised solar cells...
(Date:12/1/2009)... like a bad cold, can spread among groups of peopl...ersity of California-San Diego and Harvard shows.,...y that has been following health conditions for mo...nely people tend to share their loneliness with ot...onnected people moves to the fringes of social net...
Breaking Biology News(10 mins):Yehezkel Ben-Ari, winner of the 2009 INSERM Grand Prix 2Yehezkel Ben-Ari, winner of the 2009 INSERM Grand Prix 3Innovation puts next-generation solar cells on the horizon 2Loneliness can be contagious 2Loneliness can be contagious 3World Day to Combat Desertification focuses on human security 8869 1World Day to Combat Desertification focuses on human security 8869 2Quest Diagnostics Announces Final Tender Offer Results 12672 1Quest Diagnostics Announces Final Tender Offer Results 12672 2Quest Diagnostics Announces Final Tender Offer Results 12672 3Ocean Spray Teams Up With the American Heart Associations Go Red For Women and Its Go Red BetterU Program 49202 1Ocean Spray Teams Up With the American Heart Associations Go Red For Women and Its Go Red BetterU Program 49202 2Ocean Spray Teams Up With the American Heart Associations Go Red For Women and Its Go Red BetterU Program 49202 3
... cells within blood vessel walls move en masse ove... that the proteins driving cell behavior are doin...sible to group them according to a few discrete fu...iversity School of Medicine have shown that distin...ple activities involved in the cells, collective m...
.... World records tumbled at the Beijing Olympics. U...ecords, knocking tenths of a second off each. Peop...st few decades, which made marathon runner Mark De... century,s massive increase in population could ac...dered whether there are absolute limits on running...
... differentiations in the metabolic make-up of the ...ovember 28 in the open-access journal PLoS Geneti... Karsten Suhre, has conducted a genome-wide associ... variants in genes involved in the breakdown of fa...y can affect individuals, susceptibility to comple...
Other Biology News:Cell movements totally modular, Stanford study shows 2Cell movements totally modular, Stanford study shows 3100-meter sprint world record could go as low as 9.48 seconds 2Study identifies genetic variants giving rise to differences in metabolism 2
...loped for affinity capture of proteins from biolog...rfaces allow differential capture of proteins acco... chip has eight different spots, allowing side-by-...ded with a unique hydrophobic coating. Ciphergen's...
...r conventional PCR and thermal gradient applicatio...rmal cycler, which features a 96-well reaction mod...ble time, temperature, and protocol options, and b...ol. The system also includes PCR tubes, iTaq DNA p...
...loped for affinity capture of proteins from biolog...rfaces allow differential capture of proteins acco... chip has eight different spots, allowing side-by-...ded with a unique hydrophobic coating. Ciphergen's...
...ny-picking capabilities, 110-120 V, uses floating ...igonucleotides, carbohydrates, lipids, and other b...array applications. This system can also be used f... diameter and for inoculating 96- or 384-well micr...
Biology Products: